活性成分
重要事件
固态
生化工程
药物
纳米技术
新产品开发
生物制药
药学
化学
药品
材料科学
工程类
业务
医学
生物技术
药理学
生物
考古
物理化学
营销
历史
作者
C. W. Doherty,Amy L. Robertson,Nicola Clear,R. Docherty
出处
期刊:The Royal Society of Chemistry eBooks
[The Royal Society of Chemistry]
日期:2023-02-03
卷期号:: 769-799
标识
DOI:10.1039/9781788018982-00769
摘要
The selection of the solid form for development is a milestone in the conversion of a new chemical entity into a drug product. An understanding of the materials science of a new active pharmaceutical is crucial at the interface of medicinal chemistry and pharmaceutical development. The physicochemical properties of a new chemical entity that impact product performance are strongly influenced by the solid state structure of the active pharmaceutical ingredient. The formation of different solid state structures (salt, co-crystal and polymorph) provides an opportunity to eliminate undesirable properties thus enabling a rapid and successful development program. In this chapter we will link new academic progress to the best current industrial practices that medicinal chemists and pharmaceutical scientists can apply in selecting the optimal solid form, along with the related pharmaceutical properties that enable the rapid advancement of new molecules to medicines.
科研通智能强力驱动
Strongly Powered by AbleSci AI